Allan Michael Jordan

7PUBLICATIONS
15CO-AUTHORS
Pharmaceutical delivery technologiesGene and molecular therapyMolecular targetsElectrical energy generation (incl. renewables, excl. photovoltaics)Biologically active molecules
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Apr 12, 2024
Breaking Bad Proteins-Discovery Approaches and the Road to Clinic for Degraders.

Corentin Bouvier, Rachel Lawrence, Francesca Cavallo

|Nov 18, 2021
Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia.

Melissa B Pappalardi, Kathryn Keenan, Mark Cockerill

|May 27, 2021
Molecularly profiled trials: toward a framework of actions for the "nil actionables".

Allan Michael Jordan

|Jan 15, 2021
Glucose 6-Phosphate Dehydrogenase from Trypanosomes: Selectivity for Steroids and Chemical Validation in Bloodstream <i>Trypanosoma brucei</i>.

Cecilia Ortíz, Francesca Moraca, Marc Laverriere

|Nov 08, 2018
Cell-Active Small Molecule Inhibitors of the DNA-Damage Repair Enzyme Poly(ADP-ribose) Glycohydrolase (PARG): Discovery and Optimization of Orally Bioavailable Quinazolinedione Sulfonamides.

Bohdan Waszkowycz, Kate M Smith, Alison E McGonagle

|Sep 12, 2017
Development of (4-Cyanophenyl)glycine Derivatives as Reversible Inhibitors of Lysine Specific Demethylase 1.

Daniel P Mould, Cristina Alli, Ulf Bremberg

Pageof 2

Frequent Collaborators

2 joint publications

Bohdan Waszkowycz

2 joint publications

Daniel P Mould

1 joint publications

Marcelo A Comini

1 joint publications

Corentin Bouvier